News & Events

UPDATE – HTG Molecular Diagnostics and Merck KGaA, Darmstadt, Germany, Enter Into a Master Companion Diagnostics Agreement

TUCSON, Ariz., Oct. 11, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, and Merck KGaA, Darmstadt, Germany, have entered a broad companion diagnostics master agreement. The initial development program agreement utilizes the HTG EdgeSeq DLBCL Cell of Origin Assay in the Merck KGaA, Darmstadt, Germany, M7583, selective and irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK), program.

Read More

HTG Molecular Diagnostics and Merck KGaA, Darmstadt, Germany, Enter Into a Master Companion Diagnostics Agreement

TUCSON, Ariz., Oct. 11, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, and Merck KGaA, Darmstadt, Germany, have entered a broad companion diagnostics master agreement. The initial development program agreement utilizes the HTG EdgeSeq DLBCL Cell of Origin Assay in the Merck KGaA, Darmstadt, Germany, M7583, selective and irreversible inhibitor of Burton’s Tyrosine Kinase (BTK), program.

Read More

Dr. Ann Hanham Joins HTG Molecular Diagnostics’ Board of Directors

TUCSON, Ariz., Aug. 29, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that Ann F. Hanham, Ph.D. has been appointed to its Board of Directors (“Board”).

Ann Hanham is a senior health care executive with experience working with both private and public companies. Dr. Hanham possesses a diverse background in global clinical and regulatory development, finance, and corporate strategy. She has extensive experience in developing pharmaceutical, diagnostic and medical device products with a proven track record of clinical and regulatory approvals, building businesses, and creating shareholder value.

Read More

HTG Molecular Diagnostics Reports Second Quarter 2016 Results

TUCSON, Ariz., Aug. 09, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments and reagents for molecular profiling applications, today reported financial results for the three and six month periods ended June 30, 2016.

Read More

HTG Molecular Diagnostics to Hold 2016 Second Quarter Financial Results Conference Call on August 9, 2016

TUCSON, Ariz., July 28, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that the Company will release 2016 second quarter financial results after market close on Tuesday, August 9, 2016. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Tuesday, August 9 to discuss these results and answer questions.

Read More

HTG Molecular Diagnostics to Present at the Canaccord Genuity Growth Conference

TUCSON, Ariz., July 28, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that its management will be presenting at the Canaccord Genuity Growth Conference on Thursday, August 11, 2016 in Boston.

Read More

HTG Molecular Diagnostics Obtains CE IVD Mark for Its HTG EdgeSeq DLBCL Cell of Origin Assay and HTG EdgeSeq System

TUCSON, Ariz., July 20, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that it has obtained CE-IVD marking for its HTG EdgeSeq DLBCL Cell of Origin Assay and next-generation sequencing (NGS) based HTG EdgeSeq system. There are approximately 79,000 non-Hodgkin lymphomas per year in the European Union, and as many as 40% of those are diagnosed as diffuse large B-cell lymphoma (DLBCL). The 2016 updates to the World Health Organization (WHO) guidelines for the classification of lymphoid neoplasms have been reported to require subtyping of DLBCL tumors as activated B‑cell (ABC) or germinal center B-cell (GCB).

Read More

HTG Molecular Diagnostics and Firalis Announce Agreement to Develop a Theranostic Tool to Predict Response to Anti-TNF-alpha Therapies for Rheumatoid Arthritis

TUCSON, Ariz. and HUNINGUE, France, July 06, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, and Firalis S.A. (“Firalis”), a provider of bioanalytical services and biomarker-based products to biopharma, to biotechnology companies, and to academia, today announced an agreement to develop a next‑generation sequencing (NGS)-based theranostic tool to identify likely non-responders from responders to anti‑TNFα therapy for rheumatoid arthritis (RA).

Read More

HTG Molecular Diagnostics Announces VERI/O Laboratory Service

TUCSON, Ariz., June 23, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced the introduction of its Tucson‑based VERI/O laboratory service, offering laboratory support for its biopharma clients in biomarker research and companion diagnostic development. The VERI/O laboratory service formalizes and expands HTG’s traditional service offerings, including molecular profiling of retrospective cohorts to support development of targeted and immuno-oncology therapies, building custom research-use-only (RUO) assays to support early stage clinical programs, and developing companion diagnostic assays for use in Phase III registration trials.

Read More

HTG Molecular Appoints New Vice President of North American Capital Sales for the HTG EdgeSeq Platform

TUCSON, Ariz., June 20, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for NGS-based molecular profiling applications, today announced the appointment of Suzanne Hill as Vice President of North American Capital Sales.

Read More

HTG Molecular Diagnostics and Cancer Genetics Announce Presentation of an Immuno-Oncology Study at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

TUCSON, Ariz. and LOS ANGELES, June 06, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, and Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the acceptance of a study by the American Society of Clinical Oncology (ASCO) for presentation at their 2016 Annual Meeting, June 3–7, 2016 in Chicago, IL.

Read More

The European Human Genetics Conference (ESHG) ‘16

Join HTG Molecular Diagnostics at the 2016 Annual ESHG meeting to learn more about HTG’s NGS-based sequencing assays that are automated on the HTG EdgeSeq system.

Read More